Overview of Financial Performance - The company reported a significant decline in overall performance for the year 2024, with total revenue of 354 million yuan, a year-on-year decrease of 31.15%. The net profit attributable to shareholders was 15.57 million yuan, down 73.9% year-on-year, and the net profit after deducting non-recurring items was 2.34 million yuan, a decrease of 95.22% year-on-year [1] - In the fourth quarter, total revenue was 108 million yuan, a year-on-year decline of 40.72%. The net profit attributable to shareholders was 7.79 million yuan, down 67.06% year-on-year, and the net profit after deducting non-recurring items was 4.22 million yuan, a decrease of 79.5% year-on-year [1] Profitability Analysis - The gross profit margin improved to 29.46%, an increase of 5.36 percentage points year-on-year. However, the net profit margin significantly decreased to 5.01%, a reduction of 61.74 percentage points year-on-year, indicating that while cost control has improved, overall profitability remains under significant pressure [2] Expense Control and Cash Flow - The proportion of the company's three expenses (financial expenses, selling expenses, and administrative expenses) relative to revenue increased significantly to 12.64%, a year-on-year increase of 62.07%. This was primarily due to increased investments in bank wealth management products, leading to reduced interest income, and higher interest expenses from bank loans [3] - The net cash flow from operating activities was 0.38 yuan per share, a year-on-year decline of 5.68%, mainly due to a significant decrease in the net amount of recovered deposits compared to the previous year [3] Asset and Liability Situation - The company's cash and cash equivalents amounted to 179 million yuan, a year-on-year decrease of 52.00%, primarily due to investments in bank wealth management products. Interest-bearing liabilities increased to 43.34 million yuan, a year-on-year increase of 123.87%, indicating an expansion in financing scale [4] - Accounts receivable stood at 352 million yuan, a year-on-year decrease of 7.96%, but still accounted for 2259.21% of profits, highlighting potential recovery risks [4] Business Composition and Regional Distribution - In terms of main business segments, revenue from conventional architectural design was 157 million yuan, accounting for 44.47% of total revenue, with a gross profit margin of 22.84%. Revenue from engineering quality inspection was 85.49 million yuan, accounting for 24.14% of total revenue, with a gross profit margin of 32.65%. The highest gross profit margin was from construction drawing review, reaching 58.11% [5] - Regionally, revenue from Anhui Province was 335 million yuan, accounting for 94.71% of total revenue, indicating a high concentration of business in the provincial market [5]

Core Viewpoint - Tianyao Pharmaceutical (600488) reported a significant decline in revenue for 2024, with total revenue of 3.215 billion yuan, a decrease of 15% year-on-year, while net profit attributable to shareholders increased by 14.01% to 133 million yuan due to a substantial reduction in sales expenses [1][2] Financial Performance - The company's sales expenses dropped from 1.051 billion yuan in 2023 to 570 million yuan in 2024, nearly halving, attributed to optimized sales models and improved efficiency in expense usage [1] - The gross profit margin was 45.45%, a decrease of 2.11% year-on-year, and operating cash flow decreased by 214 million yuan to 569 million yuan [2] - The weighted return on equity increased by 0.5 percentage points to 4.45% [2] Business Segment Performance - Revenue from core business segments declined, with steroid hormones generating 1.732 billion yuan (down 16.89%), amino acids at 296 million yuan (down 19.32%), and other formulations at 1.161 billion yuan (down 10.67%) [2] Executive Compensation - Despite the revenue decline, executive compensation increased significantly, with two executives earning over 1 million yuan; the vice president's salary rose to 1.976 million yuan, an increase of 1.638 million yuan, and the CEO's salary increased to 1.4346 million yuan, up by 1.284 million yuan [2] Shareholder Activity - In the fourth quarter of 2024, northbound funds significantly reduced their holdings in Tianyao Pharmaceutical, with a total of 15.6944 million shares, a decrease of 2.1127 million shares, representing an 11.86% decline [3]